Health Care • Biotechnology: Pharmaceutical Preparations
$14.07 ▲ +0.57
(+4.22%)
MKT CAP: $522.6M • VOL: 378.0K
52W L $9 52W H $27
CBIO // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $10.8M | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$152.6M | -$40.0M | -$39.3M |
| Operating Margin % | -80.0% | — | — |
| Net Income (GAAP) | $153.9K | $37.9K | $36.9K |
| EBITDA (Normalized) | -$151.9M | -$40.0M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$71.5M | -$31.1M | -$34.9M |
| Capital Expenditures (CapEx) | $919.0K | $10.0K | — |
| Free Cash Flow (FCF) | -$72.5M | -$31.1M | -$34.9M |
| FCF Margin % | -80.0% | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $213.2M | $34.8M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $203.0M | -$15.5M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CBIO.